• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

A clinicopathological study on diagnostic techniques for malignant mesothelioma in dogs and cats

Research Project

Project/Area Number 17580278
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Clinical veterinary science
Research InstitutionTokyo University of Agriculture and Technology

Principal Investigator

MACHIDA Noboru  Tokyo University of Agriculture and Technology, Institute of Symbiotic Science and Technology, Professor, 大学院共生科学技術研究院, 教授 (20219364)

Co-Investigator(Kenkyū-buntansha) TANAKA Ryo  Tokyo University of Agriculture and Technology, Institute of Symbiotic Science and Technology, Associate Professor, 大学院共生科学技術研究院, 助教授 (70334480)
Project Period (FY) 2005 – 2006
Project Status Completed (Fiscal Year 2006)
Budget Amount *help
¥1,300,000 (Direct Cost: ¥1,300,000)
Fiscal Year 2006: ¥500,000 (Direct Cost: ¥500,000)
Fiscal Year 2005: ¥800,000 (Direct Cost: ¥800,000)
KeywordsCanine / mesothelioma / immunohistochemistry / synovial sarcoma / lung adenocarcinoma / mammary adenocarcinoma / vimentin / cytokeratin / 体腔液 / 細胞診 / 形態計測 / 免疫細胞化学的染色 / セルブロック / 猫
Research Abstract

Mesothelioma is a malignant epithelial tumor originating from the serosal surface of body cavities and its incidence has increased in recent years. Because serosal surfaces are a common site of metastatic spread for a variety of malignant tumors from internal organs, including lung and mammary adenocarcinomas, the separation of malignant mesothelioma from such adenocarcinomas can be a major challenge. Immunohistochemistry has proven valuable for the diagnosis of malignant mesothlioma, although no specific antibodies have yet been developed that can be accepted as exclusive for these tumors. The purpose of this study was to evaluate the value of immunochemistry in the accurate diagnosis of mesothelioma.
Surgical and necropsy specimens from 7 cases of mesothelioma, 6 cases of synovial sarcoma (SS), 5 cases of lung adenocarcinoma (LA), and 14 cases of mammary adenocarcinoma (MA) were evakuated immunohistochemically. A broad spectrum monoclonal antibodies was applied: vimentin, calretinin, thrombomodulin, cytokeratin 5/6, EMA, CEA, Ber-EP4, and MOC-31. These antibodies included markers that are commonly expected to react with mesothelioma ("positive" markers and markers that are not commonly expected to react with mesothelioma ("negative" markers).
Vimentin was positive in 100% of mesothelioma, 100% of SS, 0% of LA, and 57.1% of MA.; Calretinin only in 7.1% of MA ; cytokeratin 5/6 in 100% of mesothlioma, 33.3% of SS, 100% of LA, and 100% of MA; and EMA in 14.3% of mesothelioma, 83.3% of SS, 100% of LA, and 85.7% of MA. Thrombomodulin, CEA, Ber-EP4, and Moc-31 were negative in all tumors examined in the present study. Our results demonstrate that the significant usefulness of a combination of vimentin and cytokeratin 5/6 as positive markers, and of EMA as a negative marker. The 3-antibody immunohistochemical panel showed the sensitivity of 85.7% and the specificity of 100%.

Report

(3 results)
  • 2006 Annual Research Report   Final Research Report Summary
  • 2005 Annual Research Report

URL: 

Published: 2005-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi